Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its antibody drug conjugate (ADC) LM-305, targeting GPRC5D. This marks a significant milestone for LaNova as it advances its innovative ADC into clinical development.
Targeting GPRC5D
GPRC5D (G protein-coupled receptor, class C, group 5, member D) is a member of the G protein-coupled receptors (GPCRs) family and is considered a novel drug target. As an orphan receptor with no known endogenous ligand, GPRC5D is primarily expressed in malignant bone marrow plasma cells and hair follicles, with minimal or no expression observed in normal tissues. Studies have shown that GPRC5D is specifically overexpressed in patients with multiple myeloma (MM) in a BCMA-independent manner, making it a key new target for the treatment of MM.
Potential of LM-305
As the first GPRC5D-targeting ADC to enter the clinical stage, LM-305 holds the potential to become a first-in-class molecule. This innovative ADC is designed to deliver targeted therapy to cancer cells expressing GPRC5D, offering a new therapeutic option for patients with multiple myeloma. The clinical study approved by the NMPA will evaluate the safety, tolerability, and efficacy of LM-305 in treating MM, further advancing LaNova’s efforts in oncology.-Fineline Info & Tech
